Upadacitinib对比安慰剂或阿达木单抗治疗甲氨蝶呤反应不足的类风湿关节炎患者:III期双盲随机对照试验结果
这项III期双盲随机对照试验纳入1629例对甲氨蝶呤反应不足的类风湿关节炎患者,随机接受Upadacitinib 15 mg每日一次、安慰剂或阿达木单抗40 mg隔周一次,继续背景甲氨蝶呤。第12周Upadacitinib在ACR20和DAS28-CRP<2.6两项主要终点均优于安慰剂(P≤0.001),第26周影像学进展抑制显著优于安慰剂,整体安全性与阿达木单抗相似,但带状疱疹和CPK升高在Upadacitinib组更高。
要点
- Upadacitinib 15 mg每日一次在第12周ACR20和DAS28-CRP<2.6均显著优于安慰剂。
- 第26周Upadacitinib抑制影像学进展显著优于安慰剂。
- Upadacitinib整体安全性与阿达木单抗相似,但带状疱疹和CPK升高发生率更高。
核心结论
- 在对甲氨蝶呤反应不足且继续背景甲氨蝶呤的类风湿关节炎患者中,Upadacitinib在改善体征、症状和躯体功能方面优于安慰剂和阿达木单抗。
- Upadacitinib与安慰剂相比显著抑制影像学进展。
- Upadacitinib整体安全性与阿达木单抗大致相似,但带状疱疹和CPK升高发生率更高。
研究设计与样本
- III期双盲随机对照试验纳入1629例对甲氨蝶呤反应不足的类风湿关节炎患者。
- 患者按2:2:1随机接受Upadacitinib 15 mg每日一次、安慰剂或阿达木单抗40 mg隔周一次,并继续稳定背景甲氨蝶呤。
- 主要终点为第12周Upadacitinib组对比安慰剂组的ACR20应答和DAS28-CRP<2.6,第26周评估影像学进展抑制。
主要发现
- 第12周Upadacitinib组ACR20应答率为71%,安慰剂组为36%;DAS28-CRP<2.6分别为29%和6%(P≤0.001)。
- 基于ACR50应答率、DAS28-CRP≤3.2、疼痛严重度评分变化和HAQ残疾指数变化,Upadacitinib优于阿达木单抗。
- 第26周Upadacitinib组达到低疾病活动度或缓解的患者多于安慰剂组或阿达木单抗组(P≤0.001)。
- 第26周Upadacitinib组影像学进展显著受抑,且出现影像学进展的患者少于安慰剂组(P≤0.001)。
- 截至第26周,Upadacitinib与阿达木单抗组不良事件(包括严重感染)相当;带状疱疹和CPK升高在Upadacitinib组最高。
关键数值与推荐
- 主要终点第12周ACR20和DAS28-CRP<2.6在Upadacitinib对比安慰剂均达到(P≤0.001)。
- 第12周ACR20应答率Upadacitinib组71% vs 安慰剂组36%。
- 第12周DAS28-CRP<2.6比例Upadacitinib组29% vs 安慰剂组6%。
- 第26周低疾病活动度或缓解率Upadacitinib组高于安慰剂组和阿达木单抗组(P≤0.001)。
- 截至第26周,严重不良事件和导致停药的不良事件比例在阿达木单抗组最高;带状疱疹和CPK升高比例在Upadacitinib组最高。
临床怎么用
- 对甲氨蝶呤反应不足的类风湿关节炎患者,Upadacitinib 15 mg每日一次联合甲氨蝶呤可考虑作为改善症状和抑制影像学进展的治疗选择。
- 使用Upadacitinib时应关注带状疱疹和CPK升高的风险。
- Upadacitinib整体安全性与阿达木单抗相似,但需个体化评估后选择。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1-selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an inadequate response to methotrexate (MTX). METHODS: In total, 1,629 RA patients with an inadequate response to MTX were randomized (2:2:1) to receive upadacitinib (15 mg once daily), placebo, or adalimumab (40 mg every other week) while continuing to take a stable background dose of MTX. The primary end points were achievement of an American College of Rheumatology 20% (ACR20) improvement response and a Disease Activity Score in 28 joints using C-reactive protein level (DAS28-CRP) of <2.6 in the upadacitinib group compared to the placebo group at week 12; inhibition of radiographic progression was evaluated at week 26. The study was also designed and powered to test for the noninferiority and superiority of upadacitinib compared to adalimumab, as measured both clinically and functionally. RESULTS: At week 12, both primary end points were met in patients receiving upadacitinib compared to those receiving placebo (P ≤ 0.001). An ACR20 improvement response was achieved by 71% of patients in the upadacitinib group compared to 36% in the placebo group, and a DAS28-CRP score of <2.6 was observed in 29% of patients receiving upadacitinib compared to 6% of patients receiving placebo. Upadacitinib was superior to adalimumab based on the ACR50 response rate, achievement of a DAS28-CRP score of ≤3.2, change in pain severity score, and change in the Health Assessment Questionnaire disability index. At week 26, more patients receiving upadacitinib than those receiving placebo or adalimumab achieved low disease activity or remission (P ≤ 0.001). Radiographic progression was significantly inhibited in patients receiving upadacitinib and was observed in fewer upadacitinib-treated patients than placebo-treated patients (P ≤ 0.001). Up to week 26, adverse events (AEs), including serious infections, were comparable between the upadacitinib and adalimumab groups. The proportions of patients with serious AEs and AEs leading to discontinuation were highest in the adalimumab group; the proportions of patients with herpes zoster and those with creatine phosphokinase (CPK) elevations were highest in the upadacitinib group. Three malignancies, 5 major adverse cardiovascular events, and 4 deaths were reported among the groups, but none occurred in patients receiving upadacitinib. Six venous thromboembolic events were reported (1 in the placebo group, 2 in the upadacitinib group, and 3 in the adalimumab group). CONCLUSION: Upadacitinib was superior to placebo and adalimumab for improving signs, symptoms, and physical function in RA patients who were receiving background MTX. In addition, radiographic progression was significantly inhibited by upadacitinib as compared to placebo. The overall safety profile of upadacitinib was generally similar to that of adalimumab, except for higher rates of herpes zoster and CPK elevations in patients receiving upadacitinib.
引用
- Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019. PMID: 31287230. doi:10.1002/art.41032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。